Cargando…
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study
AIMS: Most studies on the primary prevention of cardiovascular disease (CVD) have been limited to patients at high CVD risk. We assessed the achievement of treatment goals for CVD risk factors among patients with a substantial variation in CVD risk. METHODS AND RESULTS: This study was conducted with...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164103/ https://www.ncbi.nlm.nih.gov/pubmed/21471134 http://dx.doi.org/10.1093/eurheartj/ehr080 |
_version_ | 1782211009298038784 |
---|---|
author | Banegas, José R. López-García, Esther Dallongeville, Jean Guallar, Eliseo Halcox, Julian P. Borghi, Claudio Massó-González, Elvira L. Jiménez, Francisco J. Perk, Joep Steg, Philippe Gabriel De Backer, Guy Rodríguez-Artalejo, Fernando |
author_facet | Banegas, José R. López-García, Esther Dallongeville, Jean Guallar, Eliseo Halcox, Julian P. Borghi, Claudio Massó-González, Elvira L. Jiménez, Francisco J. Perk, Joep Steg, Philippe Gabriel De Backer, Guy Rodríguez-Artalejo, Fernando |
author_sort | Banegas, José R. |
collection | PubMed |
description | AIMS: Most studies on the primary prevention of cardiovascular disease (CVD) have been limited to patients at high CVD risk. We assessed the achievement of treatment goals for CVD risk factors among patients with a substantial variation in CVD risk. METHODS AND RESULTS: This study was conducted with 7641 outpatients aged ≥50 years, free of clinical CVD and with at least one major CVD risk factor, selected from 12 European countries in 2009. Risk factor definition and treatment goals were based on the 2007 European guidelines on CVD prevention. Cholesterol fractions and glycated haemoglobin (HbA1c) were measured in a central laboratory. Cardiovascular disease risk was estimated with the SCORE equation. Patients' mean age was 63 years (48% men), and 40.1% had a high CVD risk. Among treated hypertensives (94.2%), only 38.8% achieved the blood pressure target of <140/90 mmHg [between-country range (BCR): 32.1–47.5%]. Among treated dyslipidaemic patients (74.4%), 41.2% attained both the total- and LDL-cholesterol target of <5 and <3 mmol/L, respectively (BCR: 24.3–68.4%). Among treated type 2 diabetic patients (87.2%), 36.7% achieved the <6.5% HbA1c target (BCR: 23.4–48.4%). Among obese patients on non-pharmacological treatment (92.2%), 24.7% reached the body mass index target of <30 kg/m(2) (BCR: 12.7–37.1%). About one-third of controlled patients on treatment were still at high remaining CVD risk. Although most patients were advised to reduce excess weight and to follow a low-calorie diet, less than half received written recommendations. CONCLUSIONS: In Europe, a large proportion of patients in primary prevention have CVD risk factors that remain uncontrolled, and lifestyle counselling is not well implemented; moreover, there is substantial between-country variation, which indicates additional room for improvement. Raised residual CVD risk is relatively frequent among patients despite control of their primary risk factors and should be addressed. |
format | Online Article Text |
id | pubmed-3164103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-31641032011-09-01 Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study Banegas, José R. López-García, Esther Dallongeville, Jean Guallar, Eliseo Halcox, Julian P. Borghi, Claudio Massó-González, Elvira L. Jiménez, Francisco J. Perk, Joep Steg, Philippe Gabriel De Backer, Guy Rodríguez-Artalejo, Fernando Eur Heart J Clinical Research AIMS: Most studies on the primary prevention of cardiovascular disease (CVD) have been limited to patients at high CVD risk. We assessed the achievement of treatment goals for CVD risk factors among patients with a substantial variation in CVD risk. METHODS AND RESULTS: This study was conducted with 7641 outpatients aged ≥50 years, free of clinical CVD and with at least one major CVD risk factor, selected from 12 European countries in 2009. Risk factor definition and treatment goals were based on the 2007 European guidelines on CVD prevention. Cholesterol fractions and glycated haemoglobin (HbA1c) were measured in a central laboratory. Cardiovascular disease risk was estimated with the SCORE equation. Patients' mean age was 63 years (48% men), and 40.1% had a high CVD risk. Among treated hypertensives (94.2%), only 38.8% achieved the blood pressure target of <140/90 mmHg [between-country range (BCR): 32.1–47.5%]. Among treated dyslipidaemic patients (74.4%), 41.2% attained both the total- and LDL-cholesterol target of <5 and <3 mmol/L, respectively (BCR: 24.3–68.4%). Among treated type 2 diabetic patients (87.2%), 36.7% achieved the <6.5% HbA1c target (BCR: 23.4–48.4%). Among obese patients on non-pharmacological treatment (92.2%), 24.7% reached the body mass index target of <30 kg/m(2) (BCR: 12.7–37.1%). About one-third of controlled patients on treatment were still at high remaining CVD risk. Although most patients were advised to reduce excess weight and to follow a low-calorie diet, less than half received written recommendations. CONCLUSIONS: In Europe, a large proportion of patients in primary prevention have CVD risk factors that remain uncontrolled, and lifestyle counselling is not well implemented; moreover, there is substantial between-country variation, which indicates additional room for improvement. Raised residual CVD risk is relatively frequent among patients despite control of their primary risk factors and should be addressed. Oxford University Press 2011-09 2011-04-06 /pmc/articles/PMC3164103/ /pubmed/21471134 http://dx.doi.org/10.1093/eurheartj/ehr080 Text en Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2011. For permissions please email: journals.permissions@oup.com. http://creativecommons.org/licenses/by-nc/2.0/uk/ The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Research Banegas, José R. López-García, Esther Dallongeville, Jean Guallar, Eliseo Halcox, Julian P. Borghi, Claudio Massó-González, Elvira L. Jiménez, Francisco J. Perk, Joep Steg, Philippe Gabriel De Backer, Guy Rodríguez-Artalejo, Fernando Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study |
title | Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study |
title_full | Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study |
title_fullStr | Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study |
title_full_unstemmed | Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study |
title_short | Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study |
title_sort | achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across europe: the eurika study |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164103/ https://www.ncbi.nlm.nih.gov/pubmed/21471134 http://dx.doi.org/10.1093/eurheartj/ehr080 |
work_keys_str_mv | AT banegasjoser achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT lopezgarciaesther achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT dallongevillejean achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT guallareliseo achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT halcoxjulianp achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT borghiclaudio achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT massogonzalezelviral achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT jimenezfranciscoj achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT perkjoep achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT stegphilippegabriel achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT debackerguy achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy AT rodriguezartalejofernando achievementoftreatmentgoalsforprimarypreventionofcardiovasculardiseaseinclinicalpracticeacrosseuropetheeurikastudy |